Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05066685 · ClinicalTrials.gov registry record
Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 18,457
- Enrollment target
NCT05066685 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 18,457 participants.
The verdict
NCT05066685 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 18,457 participants
- Enrollment target
Study Summary
The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.
Interventions
- OTHER All participants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,457 participants |
| Start Date | 2020-08-11 |
| Est. Completion | 2020-09-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05066685
The ClinicalTrials.gov registry entry for NCT05066685 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 18,457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which All participants is the first listed.
NCT05066685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05066685 about?
NCT05066685 is a clinical study titled "Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program". The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.
What is the current status of trial NCT05066685?
This trial is currently completed. The enrollment target is 18,457 participants. The study started on 2020-08-11. Estimated completion is 2020-09-25.
What interventions are being tested in trial NCT05066685?
The interventions under investigation include: All participants (OTHER).
Who is sponsoring clinical trial NCT05066685?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.